Loading data for SRPT — first visit, this takes a few seconds.

Alerta

Sarepta Therapeutics Inc. (SRPT)

NasdaqGS: SRPT · Precio en tiempo real · USD

20.86

-0.73 (-3.38%)

Al cierre: Aug 28, 2026, 8:00 PM

21.05

+0.91%

Fuera de horario: 7:30 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-3.38% (1D)

No hay datos disponibles

Precio de compra	16.14
Capitalización de mercado	2.2B
Ingresos (TTM)	1.97B
Beneficio neto (TTM)	-136.72M
	0.20
	-1.52
	n/a
	8.12
P/B (TTM)	1.44
P/S (TTM)	1.12
Fecha de resultados	Nov 4, 2026

Precio de venta	22.55
Volumen	3,612,129
Volumen medio (20D)	3,344,095
Abierto	21.45
Anterior Cerrar	21.59
Rango del día	20.83 - 22.58
Rango de 52 semanas	14.68 - 25.32
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in ...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jun 4, 1997

Empleados 835

Bolsa de Valores NasdaqGS

Símbolo bursátil SRPT

Sitio web https://www.sarepta.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Sarepta Therapeutics fueron 2.2B, un aumento de 15.58% en comparación con 1.9B del año anterior. Las ganancias fueron -713.41M, una disminución de -403.27%.

Estados financieros

Sorpresa de resultados

Sarepta Therapeutics ha publicado sus resultados trimestrales en Aug 5, 2026:

Ingresos de $401.25M falla las estimaciones por $0, con -34.34% Disminución interanual.
EPS de 0.64 supera las estimaciones en 0.15, con -68.32% Disminución interanual.

Próxima publicación de resultados

Está previsto que Sarepta Therapeutics Inc. publique sus resultados el Nov 4, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 días hace · Stocktwits

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

3 días hace · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

4 días hace · Simply Wall St.

Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value

Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation che...

5 días hace · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

5 días hace · Zacks

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Página 1 de 2

Sarepta Therapeutics Inc. (SRPT)